Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovantâs second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. Source
No articles found.
We are a late-stage biopharmaceutical company dedicated to bringing transformative...
We are a late-stage biopharmaceutical company d...
Advaxis was founded on the vision that no one should suffer from the burdens of ca...
Advaxis was founded on the vision that no one s...
SmileDirectClub was founded on one simple belief: everyone deserves a smile they l...
SmileDirectClub was founded on one simple belie...
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...
Gossamer Bio is a clinical-stage biopharmaceuti...
Join the National Investor Network and get the latest information with your interests in mind.